We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Lonza Launches PowerCHO Advance™ Media

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

The new PowerCHO Advance™ Media line offers easy filterability, improved cell-growth promotion and high protein titers. In addition to being hydrolysate-free, serum-free and of non-animal origin, the PowerCHO Advance™ Media offerings are now further enhanced to better support high-density CHO cells in suspension. For therapeutic bioprocessing applications, this medium also facilitates both downstream purification and regulatory compliance.

PowerCHO Advance™ Media allow for easy scalability, so users do not need to change to a new medium as they progress from research projects through to large-scale production. The medium is also fully chemically defined, which eases the regulatory process when transitioning from research into clinical trials and U.S. Food and Drug Administration (FDA) submission. The balanced formulation allows users to maintain high viability (greater than 90%), even at high cell densities while it has also been shown to provide higher protein titer when compared with leading media formulations on the market. 

Amber Jones, Lonza’s Product Manager Media, explains: “The addition of PowerCHO Advance™ Media offerings demonstrates Lonza’s commitment to providing scientists efficient, reliable, cost-effective cell culture media that can be used throughout the research process and beyond.”